Table of Contents
- Overview of the ATIRMOCICLIB study
- Who the trial is for
- What treatment combinations are being studied
- What the researchers are measuring
- Trial phase and study design
- Key patient-focused points
Overview of the ATIRMOCICLIB study
The clinical trial data describe an interventional study called MORPHEUS-panBC, which is evaluating multiple treatment combinations in people with metastatic breast cancer.[1] The study status is Authorised and the planned enrollment is 325 participants.[1]
This trial includes metastatic breast cancer across several subtypes, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2-positive or HER2-low breast cancer (HER2+/HER2-low BC).[1]
Who the trial is for
The study is designed for patients with metastatic breast cancer, meaning breast cancer that has spread to other parts of the body.[1] The trial data also show that the study is not limited to one breast cancer type, because it includes TNBC, HR+ BC, and HER2-positive or HER2-low disease.[1]
These subtypes matter because breast cancer is not one single disease. Different subtypes can behave differently and may respond differently to treatment combinations.[1]
What treatment combinations are being studied
The trial is looking at multiple treatment combinations, not just one treatment plan.[1] The source lists several drugs used in different combinations, including RO7881583, empagliflozin, fulvestrant, sacituzumab govitecan, Verzenios, palbociclib, inavolisib, Tecentriq, letrozole, RoActemra, Kisqali, Abraxane, ACTEMRA, and metformin.[1]
Some of these drugs are given by mouth, while others are given as an injection or infusion.[1] The trial data do not explain the exact combination for each participant in the source provided, but they show that the study is testing several regimens within the same research program.[1]
What the researchers are measuring
The main early efficacy measure in Stage 1 is objective response rate (ORR), which means the percentage of patients whose cancer shrinks or disappears during treatment.[1] This helps researchers see whether a treatment combination shows signs of working.[1]
Safety is also a major focus. The study measures the incidence, nature, and severity of adverse events, as well as laboratory abnormalities, and grades severity using NCI CTCAE v4.0.[1] In simple terms, this means the study tracks side effects, how serious they are, and whether blood or other test results change in a concerning way.[1]
The trial also measures changes from baseline in vital signs, ECG parameters, and targeted clinical laboratory test results in Stage 1 and Stage 2.[1] Baseline means the measurements taken before treatment starts.[1]
Trial phase and study design
This is a Phase 1 trial.[1] Phase 1 studies are early research studies that mainly check safety and look for early signs of benefit.[1]
The study is interventional, which means the researchers assign treatments rather than only observing what happens in routine care.[1] The brief summary says Stage 1 is used to evaluate both efficacy and safety of the treatment combinations.[1]
Key patient-focused points
The trial is about ATIRMOCICLIB research in metastatic breast cancer, not a general drug review.[1]
The study includes several breast cancer subtypes, so it is trying to learn how treatment combinations work across different patient groups.[1]
The main questions are whether the treatment combinations help shrink cancer and whether they can be given safely.[1]
Researchers are also watching heart tracing results, blood tests, and vital signs to look for treatment-related changes.[1]
The planned enrollment of 325 participants suggests a fairly large early-stage trial program for this disease setting.[1]
